Alumis Inc. (NASDAQ:ALMS) stock is trading lower after the company released topline data from its Phase 2b LUMUS trial evaluating envudeucitinib in moderate-to-severe systemic lupus erythematosus.
The study did not meet primary or secondary endpoints across the overall trial population.
Notably, key clinical insights from this trial established a clear path forward for regulatory engagement on Phase 3 development.
Subgroup Efficacy Drives Regulatory Path
A prespecified subgroup analysis revealed robust clinical responses among trial patients with a high interferon gene signature.
Within this target population, envudeucitinib successfully met the primary endpoint, measured by the British Isles Lupus Assessment Group–based Composite Lupus Assessment.
The candidate treatment also reached key secondary efficacy endpoints, including the SLE Responder Index 4, Cutaneous Lupus Erythematosus Disease Area and Severity Index 50, and Lupus Low Disease Activity State.
Patient Composition Influences Overall Results
Investigators classified trial participants using a commercially available interferon gene signature assay.
Patients with high signatures represent the majority of moderate-to-severe systemic lupus cases, typically respond more favorably to targeted interferon therapies, and show lower placebo response rates.
In the LUMUS trial, high signature patients were unexpectedly under-represented, which reduced response rates across the total study population.
Positive Pharmacodynamic Data And Safety Profile
Patient pharmacodynamic data confirmed strong, dose-dependent target engagement within the biological pathway, demonstrating maximal suppression at the highest dose of 40mg twice-daily.
Envudeucitinib was well tolerated during the trial and demonstrated a favorable safety profile with no new safety signals identified.
ALMS Price Action: Alumis shares were down 54.84% at $9.850 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment